Cardiovascular Disease

Stem Cells International
Volume 2012 (2012), Article ID 175979, 11 pages

Manuel Mazo, Miriam Araña, Beatriz Pelacho, and Felipe Prosper.
Department of Hematology and Cell Therapy, Clínica Universidad de Navarra, Foundation for Applied Medical Research, University of Navarra, Avenida Pío XII 36, Pamplona, 31008 Navarra, Spain
Received 1 September 2011; Accepted 13 October 2011Academic Editor: Wolfgang Wagner Copyright © 2012 Manuel Mazo et al.

In recent years, the incredible boost in stem cell research has kindled the expectations of both patients and physicians. Mesenchymal progenitors, owing to their availability, ease of manipulation, and therapeutic potential, have become one of the most attractive options for the treatment of a wide range of diseases, from cartilage defects to cardiac disorders. Moreover, their immunomodulatory capacity has opened up their allogenic use, consequently broadening the possibilities for their application. In this review, we will focus on their use in the therapy of myocardial infarction, looking at their characteristics, in vitro and in vivo mechanisms of action, as well as clinical trials.